Please assess the completion status of the following clinical trial:

Trial Title: Glucose and Lipid Metabolism on Antipsychotic Medication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18-60 years~* Patients: otherwise healthy and meets DSM-IV criteria for schizophrenia or schizoaffective disorder, any type, treated with haloperidol, olanzapine, clozapine, quetiapine, ziprasidone, aripiprazole, or risperidone for at least 3 months~* Controls: healthy~* Able to give informed consent~* No antipsychotic medication changes for 3 months, and no other medication changes for 2 weeks prior to Baseline Evaluations.~Exclusion Criteria:~* Axis I psychiatric disorder criteria met in self except for substance use disorders as below~* Patients and controls: meets DSM-IV criteria for the diagnoses of substance abuse within the past 3 months~* Involuntary legal status (as per Missouri law)~* The presence of any serious medical disorder that may confound the assessment of relevant biologic measures or diagnosis, including: significant organ system dysfunction, metabolic diseases, type 1 diabetes mellitus, symptomatic type 2 diabetes mellitus (see below), pregnancy, endocrine disease, coagulopathy, clinically significant anemia, that would preclude blood sampling (as determined by the PI) or acute infection;~* Patients taking more than one atypical antipsychotic medication;~* Subjects taking certain prescription medications (as determined by PI on a case by case basis).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Olanzapine (Type: ACTIVE_COMPARATOR): Participants in this group were randomized to flexibly-dosed treatment with olanzapine.
- Risperidone (Type: ACTIVE_COMPARATOR): Participants in this group were randomized to flexibly-dosed treatment with risperidone.
- Quetiapine (Type: ACTIVE_COMPARATOR): Participants in this group were randomized to flexibly-dosed treatment with quetiapine.
- Ziprasidone (Type: ACTIVE_COMPARATOR): Participants in this group were randomized to flexibly-dosed treatment with ziprasidone.

Based on this trial design, predict the completion outcome and termination type (if applicable).